Welcome to Markets Desk, here's what's moving the conversation today.
Wall Street analysts are making a bold call on argenx, the immunology biotech behind the Vyvgart franchise, projecting the stock could climb twenty three percent over the next twelve months. The thesis rests on strong and accelerating sales momentum from Vyvgart, which treats rare autoimmune conditions, giving the company a durable revenue runway that analysts believe the market is still underpricing.
Shifting to the ETF space, the long-running debate between Vanguard's VOO and VTI is getting fresh attention, with both funds carrying heavy exposure to megacap names like Nvidia and Microsoft. The core question for long-term investors is whether broader total-market coverage through VTI meaningfully diversifies risk, or whether VOO's tighter S-and-P five hundred focus delivers cleaner, more concentrated upside over a decade-long horizon.
And on the theme of overlooked opportunities, a new analysis is making the case for three under-the-radar names — ADM, Sanmina, and Delek US Holdings — each carrying high institutional ownership alongside distinct catalysts ranging from artificial intelligence integration to margin expansion. The argument is that smart money has quietly been building positions while retail attention remains elsewhere.
That's the tape. Markets Desk, signing off the floor.
